Turkey Pharmaceuticals & Healthcare Report Q3 2013 - New Market Study Published
Despite pricing decrees in the last months of 2009, 2010 and 2011, BMI still believes the market is attractive in the long term, particularly in comparison with the stagnant growth expected in developed Europe. We believe that, provided drugmakers are prepared to sell pharmaceuticals well below the average European price and can control costs to achieve this, there will continue to be strong revenuegenerating potential in the Turkish market as higher year-on-year (y-o-y) growth rates return from 2013/14.
View full press release